o_19jvdjqelic71fl1ielsj5814a.pdf

Frontier Pharma:
Psoriasis - Identifying
and Commercializing
First-in-Class
Innovation

Summary
GBI Research has released the pharma report: “Frontier Pharma: Psoriasis - Identifying and
Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class
innovation in the psoriasis development pipeline.
Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis
has increased emphasis on developing immuneomodulating therapies, as opposed to largely
symptomatic treatments. This is currently reflected in a competitive market dominated by
multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and
generic small-molecule therapies. Despite this, there are significant unmet needs in the
market, including safety concerns regarding immunomodulation. This is a particularly
important issue for the long-term commercial and clinical success of psoriatic therapeutics,
especially for emerging biologics. Another unmet need is ease of drug application, as biologic
drug delivery is invasive and painful.

Summary
This allows for pipeline programs that offer a more refined approach to immunomodulation
and ease of drug application to gain market share upon entry. In a pipeline of over 200
programs, approximately one third exhibits a novel mechanism of action. Innovative
programs target a wide range of molecules implicated in immune signaling, such as
cytokines and B and T cell antigens. Several promising first-in-class therapies can selectively
modulate specific subsets of immune cells without compromising the entire immune
system. In particular, biologics that target a subset of T cells, which are strongly implicated
in autoimmune pathophysiology, could allow for specificity of immune suppression and
thereby reduce adverse side effects. Based on clinical trials, IL-17-targeted therapies have
demonstrated superiority over currently established therapies in achieving advanced
clinical endpoints.
Get more about this report at: http://www.bigmarketresearch.com/frontier-pharmapsoriasis-identifying-and-commercializing-first-in-class-innovation-market

Scope
• A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of
pharmacotherapy
• The changing molecular target landscape between market and pipeline and particular
focal points of innovation
• Overview of how innovative products are contributing to the pipeline and market for
psoriasis
• Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis
of phase distribution, molecule type, molecular target, and administration route
• Identification and assessment of first-in-class molecular targets with a particular focus
on early-stage programs of which clinical utility has yet to be evaluated, as well as
literature reviews on novel molecular targets
• Assessment of the licensing and co-development deals for psoriasis therapies
To Get More Details Enquire @ http://www.bigmarketresearch.com/reportenquiry/132449

Table Of Content
1 Table of Contents
2 The Case for Innovation 7
3 Clinical and Commercial Landscape 9
4 Assessment of Psoriasis Pipeline and Innovation 27
5 First-in-Class Target and Pipeline Program Evaluation 40
6 Deals and Strategic Consolidations 59
7 Appendix 66

FOR MORE DETAILS
Visit us at :
http://www.bigmarketresearch.com/frontier-pharma-psoriasisidentifying-and-commercializing-first-in-class-innovation-market
Stay With Us:
TELEPHONE: +1 (855) 711-1555
E-MAIL: sales@bigmarketresearch.com
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States